A Phase 1 Study of MORAb-003 in Patients With Solid Tumor.

Trial Profile

A Phase 1 Study of MORAb-003 in Patients With Solid Tumor.

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2014

At a glance

  • Drugs Farletuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 22 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Dec 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 12 Dec 2012 Planned number of patients changed from 24 to 16 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top